Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR-002 in Advanced Solid Tumors
NCT07909031Phase 2Recruiting
- Sponsor
- Crescent Biopharma
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of CR-002 in head and neck squamous cell carcinoma (HNSCC), gastric cancer (GC), biliary tract cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC), ovarian cancer, sponsored by Crescent Biopharma. Started Oct 2026; status: recruiting.
02
Drugs
CR-002
03
Conditions
head and neck squamous cell carcinoma (HNSCC)gastric cancer (GC)biliary tract cancer (BTC)Esophageal Squamous Cell Carcinoma (ESCC)ovarian cancer
Beyond the preview
Go deeper on NCT07909031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909031.